Stocktoria
Septerna, Inc. SEPN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-10-25
Septerna, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $46.0M | $1.1M | $151,000 |
| R&D expense | $97.6M | $65.3M | $36.0M |
| Operating income | -$68.3M | -$80.8M | $2.1M |
| Income tax | $12,000 | -$498,000 | $691,000 |
| Net income | -$48.9M | -$71.8M | $4.2M |
| EPS (diluted) | $-1.10 | $-7.26 | $0.29 |
| Operating cash flow | $110.2M | -$67.5M | -$38.7M |
| Free cash flow | $109.7M | -$69.6M | -$41.6M |
| Cash & equivalents | $120.7M | $238.2M | $88.5M |
| Total assets | $596.2M | $456.6M | $130.9M |
| Total liabilities | $214.3M | $36.5M | $20.0M |
| Shareholders' equity | $381.9M | $420.0M | -$38.4M |
Growth · year-over-year · Revenue CAGR 1644.5%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +4174.5% | +611.9% | — |
| Net income growth | — | -1817.7% | — |
| EPS growth | — | -2603.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.